Global Entereg (alvimopan) Market Size By Type (12 mg Capsule, Type II), By Application (Partial bowel resection, Radical cystectomy), By Region, And Segment Forecasts, 2023 to 2032

The Global Entereg (alvimopan) Market was valued at USD 185 million in 2023 and is projected to reach USD 312 million by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. Entereg, a peripherally acting μ-opioid receptor antagonist (PAMORA), is primarily used to accelerate the time to gastrointestinal recovery following surgeries, particularly bowel resections. The market's growth is fueled by the rising number of surgical procedures worldwide, growing awareness of postoperative ileus (POI), and increasing adoption of enhanced recovery after surgery (ERAS) protocols in hospitals and surgical centers.

Drivers:

1. Rising Incidence of Postoperative Ileus:

Postoperative ileus is a common complication following abdominal surgeries, leading to prolonged hospital stays and increased healthcare costs. Entereg has demonstrated clinical effectiveness in reducing POI duration, which drives its usage.

2. Growing Adoption of ERAS Protocols:

Enhanced Recovery After Surgery protocols emphasize faster patient recovery and reduced postoperative complications. The inclusion of Entereg in these protocols is positively influencing market growth.

3. Increasing Surgical Volumes Globally:

The increasing number of gastrointestinal, colorectal, and abdominal surgeries, particularly in aging populations and high-burden healthcare systems, is significantly driving demand for Entereg.

Restraints:

1. Limited Indications and Regulatory Restrictions:

Entereg is approved only for short-term use in hospitalized patients due to cardiovascular safety concerns, which restricts its broader application across other opioid-induced constipation (OIC) indications.

2. Availability of Alternative Therapies:

The presence of other PAMORAs (such as methylnaltrexone and naloxegol) in the market offers competition and limits Entereg’s adoption outside of surgical settings.

Opportunity:

1. Expansion into Emerging Markets:

The increasing investments in surgical infrastructure and awareness in emerging markets such as Asia-Pacific and Latin America offer untapped potential for Entereg penetration.

2. Clinical Trials for Broader Indications:

Ongoing research into Entereg’s use in other forms of opioid-induced gastrointestinal dysfunction could expand its market size and applications.

Market by System Type Insights:

The market is segmented by dosage form and mechanism of action. In 2023, the capsule form accounted for the largest revenue share, driven by its convenient administration and hospital preference. The standard 12 mg oral capsule remains the most widely used formulation. Efforts to develop improved formulations or delivery systems may emerge as a secondary trend in the future.

Market by End-use Insights:

Hospitals dominated the end-use segment in 2023, accounting for over 75% of the market share. This is due to Entereg’s restricted use to inpatient settings, particularly for surgical patients. Surgical centers and specialty clinics are also notable contributors as ERAS protocols become more commonplace across healthcare settings.

Market by Regional Insights:

North America held the dominant share in 2023, driven by high surgical volumes, widespread adoption of ERAS protocols, and the availability of Entereg as a prescription drug. The U.S. remains the largest contributor due to favorable reimbursement and awareness. Asia-Pacific is expected to be the fastest-growing region, with countries like China and India investing heavily in surgical infrastructure and postoperative care enhancements.

Competitive Scenario:

Key players in the Global Entereg (alvimopan) Market include Merck & Co., Inc. (the original manufacturer), along with generics and competitors in the PAMORA class. Strategic collaborations, market exclusivity management, and real-world evidence studies are common strategies being adopted to expand market reach.

Key Developments:

2023: Several hospital networks in the U.S. integrated Entereg into ERAS pathways for colorectal surgery, showing reduced length of stay by up to 1.5 days.

2024: Emerging partnerships in Latin America aimed at distributing Entereg for public hospitals to align with enhanced surgical recovery programs.

2025: A multi-center observational study launched in Europe to assess Entereg's outcomes in minimally invasive surgeries.

Scope of Work – Global Entereg (Alvimopan) Market

FAQs:

1) What is the current market size of the Global Entereg (alvimopan) Market?

The market size was valued at USD 185 million in 2023.

2) What is the major growth driver of the Global Entereg (alvimopan) Market?

The primary driver is the increasing adoption of ERAS protocols and the clinical need to reduce postoperative ileus.

3) Which is the largest region during the forecast period in the Global Entereg (alvimopan) Market?

North America holds the largest market share due to higher surgical volumes and institutional use.

4) Which segment accounted for the largest market share in the Global Entereg (alvimopan) Market?

The Hospital segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Entereg (alvimopan) Market?

Key players include Merck & Co., Inc., and generic manufacturers, along with competitors in the PAMORA class.

Let me know if you’d like this formatted into a downloadable Word document.